Michel Vounatsos, Biogen CEO (Biogen via YouTube)
April 8, 2022 12:58 PM EDTUpdated April 11, 07:59 AM
Bioregnum

What did we learn from Bio­gen's CMS slap­down? Da­ta rule

The CMS de­ci­sion to for­mal­ly re­strict cov­er­age on Aduhelm de­ci­sive­ly ham­mered home the last nail on the Alzheimer’s drug’s com­mer­cial cof­fin. But the mut­ed im­pact …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times